Germline mutations in succinate dehydrogenase subunits B, C and D (SDHB, SDHC and SDHD), genes encoding subunits of mitochondrial complex II, cause hereditary paragangliomas and phaeochromocytomas. In SDHB (1p36)-and SDHC (1q21)-linked families, disease inheritance is autosomal dominant. In SDHD (11q23)-linked families, the disease phenotype is expressed only upon paternal transmission of the mutation, consistent with maternal imprinting. However, SDHD shows biallelic expression in brain, kidney and lymphoid tissues (Baysal et al., 2000) . Moreover, consistent loss of the wild-type (wt) maternal allele in SDHD-linked tumours suggests expression of the maternal SDHD allele in normal paraganglia. Here we demonstrate exclusive loss of the entire maternal chromosome 11 in SDHD-linked paragangliomas and phaeochromocytomas, suggesting that combined loss of the wt SDHD allele and maternal 11p region is essential for tumorigenesis. We hypothesize that this is driven by selective loss of one or more imprinted genes in the 11p15 region. In paternally, but not in maternally derived SDHD mutation carriers, this can be achieved by a single event, that is, non-disjunctional loss of the maternal chromosome 11. Thus, the exclusive paternal transmission of the disease can be explained by a somatic genetic mechanism targeting both the SDHD gene on 11q23 and a paternally imprinted gene on 11p15.5, rather than imprinting of SDHD.
Germline mutations in succinate dehydrogenase subunits B, C and D (SDHB, SDHC and SDHD), genes encoding subunits of mitochondrial complex II, cause hereditary paragangliomas and phaeochromocytomas. In SDHB (1p36)-and SDHC (1q21)-linked families, disease inheritance is autosomal dominant. In SDHD (11q23)-linked families, the disease phenotype is expressed only upon paternal transmission of the mutation, consistent with maternal imprinting. However, SDHD shows biallelic expression in brain, kidney and lymphoid tissues (Baysal et al., 2000) . Moreover, consistent loss of the wild-type (wt) maternal allele in SDHD-linked tumours suggests expression of the maternal SDHD allele in normal paraganglia. Here we demonstrate exclusive loss of the entire maternal chromosome 11 in SDHD-linked paragangliomas and phaeochromocytomas, suggesting that combined loss of the wt SDHD allele and maternal 11p region is essential for tumorigenesis. We hypothesize that this is driven by selective loss of one or more imprinted genes in the 11p15 region. In paternally, but not in maternally derived SDHD mutation carriers, this can be achieved by a single event, that is, non-disjunctional loss of the maternal chromosome 11. Thus, the exclusive paternal transmission of the disease can be explained by a somatic genetic mechanism targeting both the SDHDIntroduction Paragangliomas (PGL) of the head and neck are neuroendocrine tumours arising in branchiomeric and intravagal paraganglia. They are rare, highly vascular, mostly benign tumours usually characterized by an indolent growth pattern. Paragangliomas, like normal paraganglia, consist of two cell types: the type I or chief cells, which represent the neoplastic population in paragangliomas (van Schothorst et al., 1998a) , and the type II or sustentacular cells. The most common site is the carotid body, a chemoreceptive organ in the bifurcation of the carotid artery that senses oxygen levels in peripheral blood in a way that is not yet fully understood. Most paragangliomas appear to be sporadic, but a significant minority of the cases (10-50%) has been shown to be familial. Recently, several genes have been implicated in these familial forms of the disease. Analysis of families carrying the PGL1 gene revealed germline mutations in the succinate dehydrogenase complex-subunit D (SDHD) gene on 11q23 (Baysal et al., 2000) . This gene encodes a mitochondrial protein, an anchoring subunit of the mitochondrial respiratory chain complex II. Subsequently, mutations in other subunits of the same mitochondrial complex II were also found to be associated with hereditary paraganglioma. The SDHB gene (1p36.1-p35) encodes a catalytic subunit of mitochondrial complex II and has been implicated in familial paraganglioma of the head and neck as well as in familial paraganglioma of the adrenal medulla, better known as pheochromocytoma (Astuti et al., 2001) . Both SDHD and SDHB appear to act as tumour-suppressor genes in hereditary paraganglioma. The SDHC gene (1q21) encodes the second anchoring subunit of the mitochondrial complex II and mutations in this gene have recently been shown to cause hereditary paraganglioma as well (Niemann and Muller, 2000) . Furthermore, a hereditary paraganglioma family with linkage to a region on 11q13.1, the PGL2 locus, has been described (Mariman et al., 1993) . However, no mitochondrial complex II genes are known to be located in this region. Interestingly, strikingly different inheritance patterns have been found for paragangliomas of different genetic background. Whereas SDHB-and SDHC-linked pedigrees show autosomal dominant inheritance, SDHD-and PGL2-linked pedigrees exhibit a clear parent-of-origin effect: inheritance of paraganglioma occurs in an autosomal dominant way only when paternally transmitted, while no phenotype develops after maternal transmission. This pattern is consistent in all SDHD-linked pedigrees, and suggests sex-specific epigenetic modification of the maternal SDHD allele, consistent with genomic imprinting (van der Mey et al., 1989) . However, no evidence of a physical imprint, for example, methylation of the 11q22.1-23 region, has been found. Furthermore, the SDHD gene is biallelicly expressed in human brain, kidney and lymphoid tissue (Baysal et al., 2000) . It has been suggested that the imprinting of SDHD is restricted to the paraganglia cells, but loss of the maternal SDHD allele is frequently observed in paraganglioma from SDHD-mutation carriers, an event that is unlikely to promote tumour growth when the maternal allele is already silenced by an imprint (Baysal et al., 1997 (Baysal et al., , 2000 Dannenberg et al., 2001) . We hypothesized that somatic, selective loss of the whole maternal chromosome 11 could explain the exclusive paternal inheritance of the disease, mimicking maternal imprinting of the SDHD gene. We performed fluorescent in situ hybridisation (FISH) studies on 23 SDHD-linked tumours using different probe sets in order to test for loss of chromosome 11, and loss of heterozygosity (LOH) analysis using several microsatellite markers to determine the parental origin of the lost chromosome. Complete loss of a chromosome 11 copy was found in all tumours, and LOH analysis on a subset of seven tumours from patients for whom parental DNA samples were available revealed the exclusive maternal origin of the lost chromosome. We propose that the selective loss of the maternal chromosome 11 copy is driven by the allelic phasing of the SDHD germline mutation and a paternally imprinted tumoursuppressor gene on 11p15.
Results
We started with FISH experiments on tissue sections from five paragangliomas from D92Y carriers. The rationale for initially choosing sections rather than cell suspensions was the expectation that this would facilitate the visual selection of nuclei of the type I (chief) cells. The sections were hybridized with centromere probes for chromosomes 11 and 1, the latter chromosome serving as a ploidy reference. Loss of centromere 11 relative to centromere 1 was found in all tumours, in 45-65% of nuclei (Figure 1 ). Of the nuclei with three signals for chromosome 1, 13-54% had two signals for chromosome 11, 5-54% had one signal for chromosome 11 and 5-32% had no signals for chromosome 11. Of the nuclei with two signals for chromosome 1, 44-66% had one signal for chromosome 11 and 8-31% had no signals for chromosome 11, whereas of the nuclei with only one signal for chromosome 1, 0-7% had no signals for chromosome 11.
To exclude the possibility that loss of signals due to tissue sectioning could have interfered with the results, we next hybridized isolated whole nuclei of 10 paragangliomas, three of which were also studied in the first study. Whereas the use of suspensions precluded the selection of type I cells, evaluation of an unselected sample of 200 nuclei still demonstrated the relative loss of centromere 11 in all samples in 35-63% of nuclei (Figure 2 ). To discriminate between loss of the entire chromosome and subchromosomal loss due to complex rearrangements, we next analysed isolated whole nuclei of nine paragangliomas and two pheochromocytomas from D92Y mutation carriers that were not used in the previous studies, using a triple colour FISH technique. This allows simultaneous detection of two probes on chromosome 11 and one probe on centromere 1 (Figure 3 ). First, we studied the centromere 1 and 11 probes in combination with a BAC probe that covers the SDHD gene on 11q23 (Figure 3a and c). Concomitant loss of both probes located on chromosome 11 relative to centromere 1 was observed in all samples, in 24-65% of paraganglioma and 31-62% of pheochromocytoma nuclei ( Figure 4a ).
Next, we used BAC probes for the subtelomeric regions of 11p and 11q, with the centromere 1 probe as a reference (Figure 3b and d). Concomitant loss of both probes located on chromosome 11 relative to centromere 1 was found in 26-70% of paraganglioma and 23-54% of pheochromocytoma nuclei ( Figure 4b ). In both triple-colour experiments, loss of one of the two probes located on chromosome 11 relative to the other was observed in only a small minority of nuclei (1-7% and 2-4%, respectively), demonstrating that the observed relative loss of chromosome 11 involves the entire copy. Thus, relative loss of chromosome 11 signals was observed in all 23 tumours, ranging from 23 to 70% (mean ¼ 40%).
To determine the parental origin of the lost chromosome 11, we performed LOH analysis on seven paragangliomas and two pheochromocytomas that were also analysed by triple-colour FISH. For these cases, patient-as well as parental PBL-derived DNA samples were available. LOH analysis was performed after tumour cell populations were enriched by fluorescenceactivated cell sorting (FACS) of the aneuploid G 0,1 fraction, or the often increased G 2,M fraction of diploid tumours, with the diploid G 0,1 fraction as a reference (van der Mey et al., 1991; van Schothorst et al., 1998a) . We used three markers on 11p and five on 11q. In five paragangliomas and two pheochromocytomas, LOH analysis was informative for at least one marker on both chromosome arms. For two paragangliomas, the analysis was informative for only one marker, either on 11p or 11q. In aneuploid-or G 2,M -cell populations, all evaluable LOH experiments showed loss of maternal alleles. As expected, retention of heterozygosity was not observed (Figure 5 ). In the diploid cell populations and patient PBL DNA samples, no LOH was found (data not shown).
Discussion
The results obtained in this study demonstrate the loss of an entire copy of chromosome 11 in all investigated SDHD-linked paragangliomas. By LOH analysis, we were able to unequivocally demonstrate the maternal origin of the lost chromosome copy in a subset of seven paraganglioma and two phaeochromocytoma cases from which parental blood DNA samples were available. However, even without this direct proof, Knudson's two-hit model predicts that in case of paternal transmission of the germline mutation, loss of the wildtype maternal allele should have occurred in the tumour.
Although loss of a centromere 11 already indicates loss of the entire chromosome 11, we obtained additional evidence by the triple colour FISH experiments with telomeric probes and the 3F7 probe containing the SDHD gene. Since it was not possible to accurately discriminate type I cells in the FISH experiments on isolated nuclei, the evaluation of an unselected sample of 200 nuclei unavoidably included non-neoplastic cells as well. This explains most of the variation in loss of chromosome 11 between the different cases and the concordance of the results obtained with different probe sets for the individual tumours (Figure 4) . FISH on tissue sections, while permitting selection of type I cell nuclei, did not yield significantly higher percentages of nuclei with relative chromosome 11 loss because of loss of signals from sliced nuclei. The latter problem would have seriously complicated, if not precluded, the interpretation of triple colour FISH experiments on tissue sections and thus nuclear suspensions were used in all further experiments.
The selective loss of the entire maternal chromosome 11 explains why SDHD-linked tumours appear to arise only upon paternal transmission of the mutation, even though the SDHD gene itself is not imprinted. The latter is supported by the observed biallelic expression of SDHD in several human tissues (Baysal et al., 2000) . Although it is not uncommon for the somatic 'second hit' in the Knudson model of tumorigenesis to involve a gross chromosomal mechanism such as non-disjunctional chromosome loss, it is intriguing that in SDHDlinked paragangliomas this appears to be the preferred mechanism for the second hit. We hypothesize that a second target gene on chromosome 11, which is subject to genomic imprinting, is involved in tumour formation. A growth advantage is gained when the wild-type maternal SDHD allele on 11q23 and the active maternal copy of this second, paternally imprinted gene are lost simultaneously. As the only region known to harbour an imprinted gene cluster on chromosome 11 is 11p15, we further hypothesize that this second gene is located here.
Within that model, the most parsimonious mechanism would be a single event, viz. the loss of the entire maternal chromosome 11 copy in case of a maternal wt SDHD allele and paternal inheritance of the SDHD mutation (Figure 6a) . Loss of the maternal wt SDHD allele only, for example, by loss of a part of 11q, would not target the second tumour-suppressor gene on 11p15 and therefore not lead to tumour formation (Figure 6b ). In case of maternal inheritance of the SDHD mutation, loss of paternal alleles would not lead to tumour formation for the same reason (Figure 6c and d) . At least two events caused by different chromosomal mechanisms will be required to inactivate both SDHD and the imprinted gene on 11p15 when SDHD is maternally transmitted. These are successive loss of the paternal wild-type SDHD allele by, for example, mitotic recombination, followed by loss of the recombined paternal chromosome containing the paternal 11q23 region and the maternal 11p15 region (Figure 6e ). Given the evidence for complex LOH mechanisms in solid tumours (Devilee et al., 2001; Balmain et al., 2003) , it is somewhat surprising that the probability of this occurring in paraganglioma formation appears to be very low or zero, since no cases of maternal transmission have been reported to date. One explanation might be that the number of cell divisions in normal paraganglia is simply too low since in most head and neck paragangliomas the growth fraction is lower than 1% (Douwes Dekker et al., 2003) . Selective loss of the whole Figure 5 LOH analysis of sorted aneuploid G 0,1 or diploid G 2,M fractions of isolated nuclei of paraffin-embedded paragangliomas (P12-19) and phaeochromocytomas (Ph1-2). LOH involved the maternal allele in all cases in which the parental origin of the lost allele could be assessed (black). Retention of heterozygosity was not found for any of the informative markers maternal chromosome 11 would explain the exclusive paternal transmission of disease in paraganglioma linked to the PGL2 locus as well, because it is also located on 11q (Mariman et al., 1993) . It would also explain the absence of generation skipping of tumour susceptibility in SDHB (1p36-p35)-and SDHC (1q21)-linked families. In the latter two, loss of the maternal 11p15 region is probably also essential for tumour development, since SDHB, SDHC and SDHD encode subunits from the same mitochondrial complex. Dannenberg et al. (2001) detected loss of 11p in two out of nine sporadic paragangliomas by comparative genomic hybridization, but the mutation status of SDHB, SDHC or SDHD was not investigated. Furthermore, loss of 11p has been reported in 45% of 11 sporadic abdominal paragangliomas (Edstrom et al., 2000) . Since data on the parental origin of the 11p losses are lacking, a major role for loss of maternal 11p in sporadic paragangliomas, although likely, still remains to be proven.
Interestingly, a high percentage (86%) of loss of chromosome 11 was also found in 31/36 (86%) of Von Hippel-Lindau (VHL)-related pheochromocytomas, of which 25/31 had loss of both 11p and 11q whereas six had only 11p loss (Lui et al., 2002) . The investigators suggested that this observation might indicate the involvement of a different but essential and complementary genetic pathway in VHL-linked pheochromocytoma tumorigenesis. The results of our study emphasize a role for loss of 11p, and in particular the maternal copy, in SDHD-linked pheochromocytoma formation as well.
LOH of maternal 11p15, often with duplication of paternal 11p15, occurs frequently in human paediatric tumours including Wilm's tumours, embryonal rhabdomyosarcomas, hepatoblastoma and adrenocortical carcinomas (Gicquel et al., 1997; Tycko, 2000) . There is convincing evidence that LOH of 11p15 leads to disruption of the regulation of expression of oppositely imprinted genes, in particular H19 and IGF2, in a variety of tumours (Gicquel et al., 1997; Tycko, 2000) . The IGF2 gene product is a survival factor and strong mitogen that is overexpressed in a variety of human tumours including hereditary paragangliomas and pheochromocytomas (Stewart and Rotwein, 1996) . H19 codes for an untranslated RNA that acts a negative trans regulator of IGF2 expression (Li et al., 1998; Runge et al., 2000) .
Disruption of imprinted expression of 11p15 has also been implicated in the Beckwith-Wiedemann syndrome and focal hyperplasia of Langerhans islets causing congenital hyperinsulinism (FoCHI) (Waziri et al., 1983; Weksberg and Squire, 1996; Fournet et al., 2001) . There is an interesting parallel between our findings of maternal chromosome 11 loss in hereditary paraganglioma and loss of maternal 11p15 in FoCHI (Fournet et al., 2001 ). This disease is caused by a paternally inherited, recessive mutation of the ABCC8-or KCNJ11-gene, which is located on 11p15.4, that is, outside the imprinted region. The lesions show a strongly decreased expression of H19 and increased expression of IGF2. Thus, like in paraganglioma, a single somatic event targets the wild-type allele of a Figure 6 Model for the imprinted transmission of SDHD-linked paraganglioma. Maternal (white) and paternal (grey) chromosomes are depicted. (a) Both the maternal 11q region, containing the wt SDHD allele, and the maternal 11p region, containing the active tumour suppressor allele, are targeted. In case of an event targeting only the wt maternal SDHD allele on 11q (b), the active maternal tumour suppressor allele on 11p15 is not affected and tumour development is inhibited. In case of maternal inheritance of the SDHD mutation, a second hit targeting the wt paternal allele by, for example, a deletion of the paternal 11q region (c) or even the whole paternal chromosome 11 (d) will leave the maternal 11p15 region intact and tumour formation is not initiated. When the SDHD mutation is maternally transmitted, at least two events caused by different chromosomal mechanisms will be required to inactivate both the wt SDHD allele and the active maternal allele of the imprinted tumour-suppressor gene on 11p15, namely loss of the paternal wild-type SDHD allele by, for example, mitotic recombination, followed by loss of the recombined paternal chromosome containing the paternal 11q23 region and the maternal 11p15 region (e). Apparently, this sequence of events is very unlikely in vivo non-imprinted susceptibility gene on the maternal chromosome 11 as well as the maternally imprinted 11p15 region, and in both types of diseases this results in exclusive paternal transmission. Although the development of solid tumours in general is a multi-step genetic evolution process, it is unclear why tumour development in SDHD mutation carriers specifically requires loss of a putative maternally expressed tumour-suppressor gene, in addition to loss of wt SDHD. It has been speculated that the tumorigenic effects of SDHD inactivation might be explained by either mitogenic effects of elevated levels of reactive oxygen species or blocking of apoptosis due to mitochondrial dysfunction (Astrom et al., 2003; Eng et al., 2003) . On the other hand, oxidative stress may trigger pro-apoptotic signalling and create a selection pressure for mutational activation of antiapoptotic pathways. Since the IGF pathway has found to be involved in antiapoptotic signalling, loss of the maternally expressed H19 gene, a known suppressor of IGF2, might be an essential step in paraganglioma development (Datta et al., 1997; Burns and Hassan, 2001) .
SDHD-linked paraganglioma is a striking, and to our knowledge, first example of the effect of allelic phasing on the penetrance of a hereditary tumour syndrome in man. Recently, allelic phasing of mouse chromosome 11 deficiency was found to influence p53 tumorigenicity (Biggs et al., 2003) . The deletion on chromosome 11 elevated the tumour susceptibility and modified the tumour spectrum when in trans with the p53 mutation. Many genes display differential expression of parental alleles, due to genomic imprinting or genetic regulation (Schadt et al., 2003) . Conceivably, a certain dosage ratio of cancer-related alleles, which are coincidentally located on the same chromosome in cis-configuration, may provide a selective growth advantage. The tumorigenic potential of acquired chromosome aneuploidy, a hallmark of many solid tumours, would then be dependent on the allelic phasing or imprinting status of these genes. Our study provides a clear-cut example of this mechanism, which might also apply to an individual's overall susceptibility to more common forms of cancer.
Materials and methods

Patients and families
Diagnosis of paraganglioma was based on medical history, physical and otolaryngological examination, radiological imaging and histopathology of the excised tumour. After obtaining informed consent, peripheral blood was obtained from patients and their parents for genomic DNA isolation. Routinely processed archival paraffin-embedded carotid body paraganglioma or phaeochromocytoma tissue from patients with the D92Y Dutch founder mutation in the SDHD gene were obtained from the archives of the Department of Pathology of the Leiden University Medical Center (van Schothorst et al., 1998b; Baysal et al., 2000) .
Mutation detection
The D92Y mutation in the SDHD gene was detected by direct sequencing of PCR products obtained from peripheral blood lymphocyte (PBL) DNA as described previously (Baysal et al., 2000) .
Interphase FISH on paraffin-embedded tissue sections
We performed interphase FISH on paraffin-embedded sections as previously described (Haralambieva et al., 2002) . The pLC11A probe and the PUC1.77 probe for the centromeric alphoid repeat DNA of chromosomes 11 and 1, respectively, were kindly provided by Dr J Wiegant (Deptartment of Molecular Cell Biology, LUMC, Leiden, The Netherlands) (Cooke and Hindley, 1979; Waye et al., 1987) . We have chosen the PUC1.77 probe as a reference because of our extensive experience with the interpretation of the signals given by this probe and a previous LOH study did not indicate involvement of chromosome 1 in PGL1/SDHD-linked paragangliomas (Devilee et al., 1994) . The probes were labelled by standard nick translation with biotin-16-aUTP or digoxigenin-11-dUTP (Roche, Basel, Switzerland). A total of 200 nuclei were analysed for each sample by two independent investigators (EFH and ESJ).
Triple colour interphase FISH on nuclei isolated from paraffin-embedded tissue
Isolation of intact nuclei, hybridization and immunodetection were performed as previously described (Jordanova et al., 2002) , with slight modifications. The hybridization mix contained 50% formamide, 3 ng/ml of each of the three probes (either PUC1.77, pLC11A and 3F7 or PUC1.77, 371C18 and 469N6) and a 50-fold excess of human Cot-1 DNA (Invitrogen Life tech., Paisley, UK). A volume of 5 ml of the mix was applied directly onto the slides and covered with an 18 Â 18 mm 2 coverslip. After a denaturation step of 8 min at 801C, the slides were incubated overnight at 371C in a moisture chamber. The BAC probes 371C18 (telomere 11p), 469N6 (telomere 11q) and 3F7 (11q23, containing the SDHD gene) were obtained from the Children's Hospital Oakland Research Institute (Peter de Jong BAC library RP11). All probes were labelled by standard nick translation with biotin-16-aUTP, digoxigenin-11-dUTP or fluorescein-12-dUTP (Roche). A total of 200 nuclei were analysed for each sample and probe combination by two independent investigators (EFH and ESJ).
Flow cytometry analysis and flow sorting
Cell preparation and staining procedures were performed as described elsewhere (Beerman et al., 1990) . Pepsin digestion was used to isolate whole nuclei from 45 mm thick paraffin sections. Nuclei were subsequently stained with propidium iodide. DNA content was determined with a FACscan flow cytometer (Becton & Dickson, Immunocytometry Systems, San Jose, CA, USA). On average, 100.000 nuclei were measured in each sample. If the DNA histogram showed a single G 0,1 and G 2 peak both populations were subsequently sorted on a FACsorter (FACSVantage SE, Becton & Dickson, Immunocytometry Systems, San Jose, CA, USA). Owing to the G 2 arrest often detected in paraganglioma cells, the G 2,M population was considered enriched for tumour cells (Douwes Dekker et al., 2003) . If the DNA histogram showed G 0,1 peaks, the left peak was considered to represent the diploid and the right peak the aneuploid population. Cells were sorted directly into 1.5 ml microfuge tubes and DNA was subsequently isolated as previously described (Abeln et al., 1994) .
Loh analysis
LOH analysis was performed as previously described (van Schothorst et al., 1998a) . Genotypes of patients and their parents were established for the markers D11S1984 and D11S2362 (11p15), D11S4183 (11p11), D11S1335, D11S1765 and D11S4075 (11q13) and D11S1647, D11S3178 and pDJ159Ogt1R (11q23). Markers were informative if they were heterozygous in the patient, and the parental origin of the alleles could be unambiguously derived. Subsequently, in informative cases both diploid and aneuploid or diploid and the G 2,M fractions were tested.
